Trial · NCT05638620
Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID
NCT05638620, Phase 1, Completed, Jonathann Kuo, MD
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID. Trials, record NCT05638620. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05638620
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID
- NCT number
- NCT05638620
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 20 participants, actual
- Lead sponsor
- Jonathann Kuo, MD
- Conditions
Post Acute COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19 Recurrent, Post-Acute COVID-19, Post-Acute COVID-19 Infection, SARS-CoV2 Infection, Post Acute Sequelae of COVID-19, Dysautonomia, Dysautonomia Like Disorder, Dysautonomia Orthostatic Hypotension Syndrome, Post COVID-19 Condition, Post-COVID Syndrome, Post COVID-19 Condition, Unspecified, Post-COVID-19 Syndrome
- Interventions
- stellate ganglion block with 0.5% bupivacaine
- First posted
- 2022-12-06
- Last updated
- 2025-03-13
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Patient-Reported Outcomes: PROMIS-29 Score | 1 month | The primary objective of the clinical effectiveness trial is to evaluate whether Dual Sympathetic Blocks performed at 0 and 1 weeks will improve patient-reported outcomes of depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities status. These domains are measured as reflected by Patient-Reported Outcomes Measurement Information System (PROMIS-29) total scores between baseline and 4 weeks |
| Primary | Depression | 1 month | PROMIS-29 survey will measure changes in each domain scores between baseline and 4 weeks. |
| Primary | Anxiety | 1 month | PROMIS-29 survey will measure changes in each domain scores between baseline and 4 weeks. |
| Primary | Physical function | 1 month | PROMIS-29 survey will measure changes in each domain scores between baseline and 4 weeks. |
| Primary | Pain interference | 1 month | PROMIS-29 survey will measure changes in each domain scores between baseline and 4 weeks. |
| Primary | Fatigue | 1 month | PROMIS-29 survey will measure changes in each domain scores between baseline and 4 weeks. |
| Primary | Sleep disturbance | 1 month | PROMIS-29 survey will measure changes in each domain scores between baseline and 4 weeks. |
| Primary | Ability to participate in social roles and activities status | 1 month | PROMIS-29 survey will measure changes in each domain scores between baseline and 4 weeks. |
| Secondary | Autonomic Symptoms: COMPASS-31 Score | 1 month | The secondary objective of the clinical effectiveness trial is to evaluate whether Dual Sympathetic Blocks performed at 0 and 1 weeks will improve Dysautonomia symptoms as reflected by corresponding Composite Autonomic Symptom Scale 31 (COMPASS-31) scores between baseline and 4 weeks |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers27
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05638620
GET https://conductscience.org/api/trials/v1/NCT05638620/papers?page=2